CEO Einar Pontén comments: “Lipum has reached a stage when we are preparing for clinical trials. Important intermediate goals have been achieved during the first half of the year. Toxicology- and safety studies are progressing according to plan as well as the upscaling of the production process of our drug candidate SOL-116”.
Financial summary January – June 2021
- Net sales: KSEK 0 (13)
- Result after financial items: KSEK -17,458 (-12,361)
- Cash and cash equivalents as of June 30: KSEK 68,729 (17,973)
Significant events during the period
- Funding and listing on the Nasdaq First North Growth Market
- Toxicology- and safety studies and production development proceeded according to plan
- The organization was strengthened with new employees and board members
Significant events after the period
- Nothing to report
Link to the full report (in Swedish): Interim report
For further information, please contact:
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: firstname.lastname@example.org, phone: +46 8 503 000 50.